KRAS and non-small cell lung carcinoma: The combined strategy of the MEK inhibitor trametinib plus the RTK inhibitor anlotinib effectively inhibits the feedback activation of ERK and results in long-term inhibition of AKT in KRAS-mutant NSCLC, preliminarily explaining the synergistic antitumor activity.